Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in retinal ganglion cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 16 Parkinson's papers of 691 | 0.63 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3343
Sealed predictions
- MAP1B in dopamine neurons, braak+0.43 (p 0.250) → +0.09 (p 0.822)receipt 3350
Swarm cases
receipt 3350: MAP1B in dopamine neurons, braak
- power
- full sample +0.28 (p 0.254, n 18), 95% CI -0.21 to +0.66. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.310, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.36 (p 0.148, n 18). could be the mix.
- skeptic
- leave-one-out range +0.20 to +0.42, sign flips 0; without severely affected donors +0.28 (p 0.254, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAP1B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts